Jak inhibitors - Open Access .click

Results 221 to 230 of about 72,228 (243)

Some of the next articles are maybe not open access.

Indian Journal of Skin Allergy, 2023
The four Janus Kinase (JAK) proteins and seven signal transducer and activator of transcription (STAT) factors mediate the intracellular signaling pathway of cytokine receptors, which are described in the pathogenesis of many autoimmune, allergic, and inflammatory dermatoses.
S. K. Shahriar Ahmed +4 more
openaire +1 more source

Emerging drug profile: JAK inhibitors

Leukemia & Lymphoma
Dysregulated JAK/STAT hyperactivity is essential to the pathogenesis of myelofibrosis, and JAK inhibitors are the first-line treatment option for many patients. There are four FDA-approved JAK inhibitors for patients with myelofibrosis. Single-agent JAK inhibition can improve splenomegaly, symptom burden, cytopenias, and possibly survival in patients ...
Alexander, Coltoff, Andrew, Kuykendall
openaire +2 more sources

[JAK Inhibitors in Rheumatology].

Deutsche medizinische Wochenschrift (1946), 2019
In Germany, baricitinib and tofacitinib have been approved for the treatment of at least moderately active rheumatoid arthritis after the failure of conventional disease modifying anti-rheumatic drugs in 2017, and tofacitinib also for psoriatic arthritis and ulcerative colitis. Both baricitinib and tofacitinib can be taken orally and reversibly inhibit
openaire +2 more sources

JAK kinase inhibitors